Answers are grounded in this paper and cite their sources.
Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: